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Abstract
Purpose of review To understand the variety of conditions in which the pericardium may be
affected in cancer patients.
Recent findings Cancer may affect the pericardium directly (primary cancer; uncommon) or
through metastases (commoner). Cancer treatment (chemotherapy and radiotherapy) may
affect the pericardium leading to pericarditis and myopericarditis. Pericardial effusions,
tamponade and constrictive pericarditis are complications that can also occur. A variety of
techniques (predominantly cardiac imaging related) are used to make the diagnosis with
the treatment strategy dependent on whether the pericardial disease is due to cancer or as
a result of cancer treatment.
Summary A variety of pericardial diseases may be caused by cancer and cancer treatment.
Determining the aetiology and providing effective treatment can often be challenging.
Introduction
Pericardial disease in cancer patients commonly mani-
fests in one of two ways. It may be amanifestation of the
disease itself, e.g. malignant disease affecting the
pericardium either directly or via a pericardial effusion
or as a result of treatment (chemotherapy or radiother-
apy). The aetiology of pericardial involvement can be
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difficult to determine (due to the dangers inherent in
pericardiocentesis and pericardial biopsy) and the man-
agement of certain conditions (recurrent pericardial ef-
fusions and constrictive pericarditis) can be very
challenging [1]. This review will cover the different types
of pericardial disease in cancer patients and the associ-
ated management options.
Pericarditis
The pericardium consists of two layers—the outer fibrous pericardium and the
inner serous pericardium. The serous layer is composed of the outer parietal
layer fused to the fibrous pericardium and the inner visceral pericardiumwhich
is fused to the epicardium. In between the parietal and visceral layers is the
pericardial space which contains the lubricating pericardial fluid (around 50ml
normally).
Pericarditis is the commonest form of pericardial disease [2, 3]. It usually
affects young and middle-aged people and often recurs [4]. It is responsible for
around 5% of presentations to emergency departments with non-ischaemic
cardiac pain [5]. Mortality rates can reach 1%. The aetiology is often unclear
as many cases are undiagnosed. Interestingly, pericarditis may be a marker of
occult cancer with over 10%of 13,759 individuals with pericarditis subsequent-
ly going on to be diagnosed with cancer in a Danish registry [6•]. The increased
risk of cancer persisted for over a year in those with pericarditis and the overall
prognosis was worse for these individuals who went on to be diagnosed with
cancer. Cancer-related causes include primary tumours (e.g. pericardial meso-
thelioma (rare) or secondary tumours (lung and breast primaries and
lymphoma)).
Radiotherapy-induced pericarditis occurs acutely in animal models [7].
The underlying cancer lesion and as such direction of radiotherapy beam
can influence the incidence of pericarditis with an increase in incidence
ratio of 1.61 (1.06–2.43) in left-sided breast tumours compared to right-
sided breast tumours [7, 8]. While radiotherapy-induced pericarditis can
occur early [9], the maximal incidence was at 5–9 years in a study of
patients receiving radiotherapy for breast cancer [10]. The treatment of
other cancers with radiotherapy can lead to pericarditis with this being
reported a few weeks after therapy in Hodgkin disease and oesophageal
cancer [11]. With longer follow-up going forwards, the incidence of
radiation-induced pericarditis may change.
The dose of radiation is important. In one review, 950% of patients who
received 9 30 Gy of radiation for a variety of diseases (Hodgkin and non-
Hodgkin lymphoma) developed pericarditis [11]. Other studies have focussed
on the area of the heart involved showing that radiation-induced pericarditis is
more likely if a large proportion of the heart (9 30%) receives a dose of at least
50 Gy [12].
Pericarditis is suspected clinically in this setting when the patient
complains of chest pain which is worse on inspiration and better when
sitting up. The ECG demonstrates widespread saddle-shaped (concave)
ST segment elevation in a non-coronary distribution. There may also be
PR segment depression. The patient is often tachycardic and pyrexial.
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Pericardial inflammation and thickening may be best visualised on
cardiac MRI (CMR) (Figs. 1 and 2 respectively). Troponin levels should
normal; if elevated, there is myocardial involvement and the diagnosis is
one of myopericarditis (see below).
The treatment of pericarditis is usually as per recommended guide-
lines [13]. However, it is to be recognised that many cancer patients
may have a predisposition to bleeding due to abnormal blood counts or
coagulation abnormalities secondary to their disease or treatment. It can
thus be challenging to introduce routine therapy such as non-steroidal
anti-inflammatory agents in this context. As a result, there is often a
greater and earlier use of other agents, e.g. colchicine and steroids
although this may not alter outcomes [14].
Fig. 1. STIR CMR image demonstrating pericardial inflammation (white arrow).
Fig. 2. Scout CMR image showing thickened pericardium around the right ventricular free wall (white arrow).
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Pericarditis can be complicated by pericardial effusions and tamponade and
in the long term by constriction (discussed below).
Myopericarditis
Myopericarditis is a condition where there is inflammation involving both
the pericardium and the myocardium. Myopericarditis can occur acutely
after anthracycline administration [15]. High-dose cyclophosphamide can
cause acute cardiotoxicity manifest as haemorrhagic myopericarditis [16].
Death has also been reported in this context associated with pericardial
effusions and tamponade [17]. Pre-existing cardiac dysfunction, older age,
use of other chemotherapeutic agents and type of cancer (e.g. lymphoma)
are all risk factors [18]. Renal impairment can increase the risk of
cyc lophosphamide-re la ted acute myoper icardi t i s [19] . Acute
myopericarditis has also been reported in the setting of ATRA (all trans
retinoic acid) use for the treatment of acute promyelocytic leukaemia [20,
21•, 22].
Diagnosis is through a combination of clinical examination, laboratory tests
and cardiac imaging investigations. The troponin levels are elevated reflecting
myocardial damage. There is a role for myocardial and/or pericardial biopsy if
the aetiology remains unclear and there is clinical deterioration. However,
cardiac biopsies are invasive procedures with a significant degree of procedural
risk.
The treatment of myopericarditis in this context depends upon the
aetiology, i.e. whether the disease is the cause or the chemotherapy. If it is the
former, aggressive treatment of the disease may result in a resolution of cardiac
complications. If it is the latter, different chemotherapeutic regimesmay need to
be used (which may be less effective cancer treatments) with the addition of
steroids. In clinical practice, the actual aetiology is often determined through a
process of elimination.
Fig. 3. Four-chamber echocardiography still demonstrating large global pericardial effusion (white arrows).
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Pericardial effusions and tamponade
Pericardial effusions complicating cancer therapy are not uncommon with 5–
15%of cancer patients having amalignant pericardial effusion and 7%having a
non-malignant pericardial effusion in a variety of series [23–25]. Any cancer can
metastasize to the pericardium resulting in an effusion with the commonest
cancers doing so being breast, lung and Hodgkin lymphoma. Mesothelioma is
the commonest primary malignant neoplasm while other primary cancers
include sarcomas and lymphomas [26•].
Pericardial effusionsmay ormay not be associated with pericarditis andmay
or may not develop acutely. If they are chronic, they may more often present
with a gradually decreasing exercise capacity and an increase in exertional
dyspnoea. If the pericardial fluid rapidly accumulates, it may cause cardiac
tamponade with acute haemodynamic compromise which requires urgent
intervention. Confirmation of the diagnosis is primarily made through echo-
cardiography (Fig. 3) which allows full assessment of the haemodynamic effects
of the effusion (Fig. 4) and also allows serial monitoring of the effusion before/
after treatment.
The treatment of the effusion depends on the acuteness of symptoms as well
as the aetiology. In cases of cardiac tamponade, urgent pericardial drainage is
required. In more chronic cases, a decision can be made based on whether the
effusion is related to treatment or is malignant. A trial of more intensive chemo-
therapy or steroids may be undertaken first to determine if this aids effusion
resolution. If not, the treatment varies between pericardiocentesis, prolonged
pericardial drainage and surgical approaches. It is important to fully evaluate
the pericardial fluid no matter which approach is taken. Fluid should be sent for
cytology and flow cytometry and consideration should be made to concomitant
pericardial biopsy (safer to perform under direct vision in the surgical setting).
Studies have suggested that the surgical treatment of malignant pericardial
effusions may offer a more definitive solution to pericardiocentesis [27, 28].
However, such approaches are associated with significant potential morbidity
Fig. 4. Transmitral Doppler profile demonstrating a 9 25% variation in flow with respiration (indicative of tamponade physiology).
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[29•, 30] and recent work has shown that percutaneous approaches may be
associated with less morbidity and a low risk of recurrence [31•]. However, a
systematic review showed that extended pericardial drainage, pericardial scle-
rosis and balloon pericardiotomy (10–12% recurrence rate) were all associated
with less recurrence than plain pericardiocentesis (38% recurrence rate) [32].
Pericardial sclerosis has been carried out with a variety of agents (tetracy-
cline, bleomycin, talc etc.) but is a painful process. Additionally, a randomised
trial showed no statistical difference between this and pericardial drainage in
terms of recurrence [33]. Pericardial sclerosis can also lead to pericardial con-
striction which is a difficult condition to treat (discussed below).
Pericardial constriction
Pericardial constriction is a condition where there is a loss of the normal
elasticity of the pericardial sac. In the context of cancer, this can occur as a result
of radiation-induced fibrosis or fibrotic change secondary to pericarditis. A
variant is effusive-constrictive pericarditis when pericardial constriction is pres-
ent along with a pericardial effusion with symptoms and signs of the former
often being masked until pericardial drainage is performed.
Clinical signs which while not pathognomonic can aid in diagnosis include
pulsus paradoxus (an exaggerated drop in systolic blood pressure of more than
10 mmHg on inspiration), Kussmaul’s sign (lack of an inspiratory decline in
JVP) and a pericardial knock (auscultated before an S3). Doppler echocardiog-
raphy and real-time CMR cines can help in diagnosis. If there remains diagnos-
tic uncertainty, equalisation of left and right ventricular diastolic pressure
tracings obtained via cardiac catheterisation reflects increased ventricular inter-
dependence and can clinch the diagnosis.
Symptoms are normally progressive and pericardiectomy remains the most
effective therapy. Surgical removal of the pericardium is technically challenging
and long-term outcomes are mixed [34]. Outcomes are worse if the pericardial
disease was due to radiation therapy [35].
Tumours of the pericardium
Pericardial tumours include primary and secondary cancers as well as benign
lesions (Table 1).
Primary pericardial tumours are rare accounting for around 10% of all
primary cardiac tumours [36•, 37] with their prevalence in the general popula-
tion being 0.001 to 0.007% [26•]. Secondary tumours or direct invasion into
the pericardium is around 1000 times more common.
Diagnostically, they can prove a challenge and the definitive diagnosis is
often obtained only after pathological analysis of tissue samples. Imaging can
help narrow the list of differentials. While CMR is the most adept at tissue
characterisation, CT can image tumour invasion of adjacent structures (Table 2).
Imaging can also guide the surgeon as to the extent of the operation required
and as to whether operative removal is feasible in the place (e.g. in cases where
there is tumour encasement of vital structures). Positron emission tomography
(PET) scanning can be very helpful in determining whether a particular lesion is
active and whether treatment has induced remission.
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Pericardial cysts (mesothelial cysts) and lipomas are the commonest benign
pericardial masses. Pericardial cysts are commonly located at the right (and left)
anterior cardiophrenic angles and are commonly asymptomatic. Removal may
be required if there are compressive symptoms. Pericardial lipomas are similarly
asymptomatic in the majority of cases. Again, symptoms if they occur are
related to compression and may in that situation require surgical removal.
Other rare and usually benign pericardial tumours include lipoblastomas,
paragangliomas, germ cell tumours, haemangiomas and fibromas.
The commonest primary cancer affecting the pericardium is mesothelioma
being present in 0.0022% in one autopsy series [38, 39]. It is more common in
men than inwomen and is usuallymanifested inmiddle to late age groups. There
is no definitive relation to asbestos exposure unlike in pleural mesothelioma.
This may manifest as tamponade and constriction [40, 41]. Mesotheliomas can
be imaged on echocardiography, cardiac CT and CMR. Resection is the treatment
of choice, but the prognosis is poor in metastatic disease [38]. Other pericardial
malignancies include lymphomas and sarcomas. Sarcomas are uncommon and
subtypes include angiosarcoma, fibrosarcoma, liposarcoma, rhabdomyosarco-
ma, synovial sarcoma and undifferentiated sarcoma. Prognosis is poor at less
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than 1 year for all patients. Pericardial lymphomas are usually of the large B cell
variety and can often be associated with a pericardial effusion. Metabolic activity
is commonly noted on PET imaging.
Pericardial metastasis should be considered when a patient with cancer
develops a pericardial effusion or pericarditis. Rarely, pericardial metastases
may be the first sign of cancer [42] or may be found incidentally in asymptom-
atic individuals [26•]. The investigations performed are similar to those for
primary pericardial neoplasms.
Summary
Cancer can affect the pericardium in a variety of ways either as a result of
primary or secondary disease or as a result of chemotherapy or radiotherapy.
The aetiology of pericardial disease in this setting can often be difficult to
determine which may result in a delay in optimal treatment being instituted.
Despite optimal treatment, some conditions may recur, e.g. pericardial effu-
sions or have a poor prognosis, e.g. constrictive pericarditis and mesothelioma.
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